ArticleOcular oncology and pathology2026
Diffuse Choroidal Hemangioma in Sturge-Weber Syndrome: Correlation between Clinical Features, Imaging, and Treatment Response.
Article in Ocular oncology and pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of this study was to describe the clinical features, multimodal imaging characteristics, treatment outcomes, and prognostic factors in patients with diffuse choroidal hemangioma (DCH) associated with Sturge-Weber syndrome (SWS)/phakomatosis pigmentovascularis (PPV) at a referral center in India. Methods: A retrospective observational study was conducted between 2013 and 2024 on patients diagnosed with SWS/PPV and associated DCH. A poor outcome was defined as a final best-corrected visual acuity (BCVA) of 20/200, persistent or recurrent exudative retinal detachment, persistent tumor, or disease recurrence. Results: A total of 29 patients (32 eyes) with SWS/PPV-associated DCH were included. The mean age at presentation was 25.3 ± 11.6 years, with a female predominance (59%). Most patients had SWS (90%), while 10% had PPV. Exudative retinal detachment and glaucoma were observed in 46% and 31% of SWS eyes, and 66% and 83% of PPV eyes, respectively. The mean tumor basal diameter and thickness were 8.31 mm and 4.16 mm at presentation. Selected cases were managed with plaque brachytherapy, trabeculectomy, external beam radiotherapy, or intravitreal anti-VEGF injections. Complete tumor regression was achieved in 22% of eyes. Mean BCVA improved significantly from 20/1200 to 20/160 at final follow-up; however, a poor visual outcome occurred in 69% of eyes. On multivariate analysis, persistent tumor ( Conclusion: DCH in SWS is a vision-threatening condition requiring individualized multimodal treatment. Although anatomical and visual improvement is achievable, recurrence and tumor persistence are common and predict poor outcomes. Thus, long-term follow-up and early intervention are critical for optimal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.